Toyo Kohan Co., Ltd.

Yamaguchi University

Mitsuyoshi Oba

Hirofumi Yamano

Ryouichi Tsunedomi

Shoichi Hazama

Yoshihiko Hamamoto

Shuichi Kamei

Hiroaki Nagano

Yusuke Fujita

Toshiya Tsuda

Hideyasu Matsuyama

Yoshiaki Yamamoto

Yukiha Ishikawa

It is intended to conveniently determine the pharmacokinetics of axitinib and to predict the therapeutic effect of axitinib. The present invention provides a method for determining the pharmacokinetics of axitinib, comprising the step of calculating a predicted pharmacokinetic parameter of axitinib using specific gene polymorphisms and background factors regarding a test subject.

Method for determining pharmacokinetics of axitinib and method for predicting therapeutic effect of axitinib based on pharmacokinetics of axitinib

In the case of using a blocking nucleic acid to prevent non-specific hybridization of a target nucleic acid with a nucleic acid probe, further excellent efficiency of detecting the target nucleic acid is achieved. A buffer composition used in hybridization of a target nucleic acid with a nucleic acid probe, wherein the buffer composition for hybridization contains a blocking nucleic acid comprising a nucleotide sequence complementary to a region comprising at least a non-detection target nucleotide in a non-target nucleic acid, in a concentration of one or more times higher than the concentration of a nucleic acid in a nucleic acid mixture consisting of the target nucleic acid and the non-target nucleic acid.

Buffer composition for hybridization and hybridization method

Growing community of inventors

Yamaguchi, Japan

Mitsuyoshi Oba